No Data
No Data
JMP Securities Maintains Inhibrx Biosciences(INBX.US) With Hold Rating
JMP Securities analyst Reni Benjamin maintains $Inhibrx Biosciences(INBX.US)$ with a hold rating.According to TipRanks data, the analyst has a success rate of 33.0% and a total average return of -9.8%
Inhibrx Biosciences: Hold Rating Justified by Financial Stability and Clinical Pipeline Potential
Inhibrx Biosciences Files to Sell 2.45M Shares of Common Stock for Holders
Inhibrx Biosciences(INBX.US) Director Buys US$997.02K in Common Stock
$Inhibrx Biosciences(INBX.US)$ Director Kayyem Jon Faiz purchased 57,549 shares of common stock on Jun 5, 2024 at an average price of $17.32 for a total value of $997.02K.Source: Announcement What is
Express News | Inhibrx Biosciences 13G Filing Shows Viking Global Investors LP Reported A 12.3% Stake In The Co As Of May 29, 2024
Express News | Viking Global Investors LP Reports 12.3% Passive Stake in Inhibrx Biosciences, Inc. as of May 29, 2024- SEC Filing